These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 7514956)
1. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956 [TBL] [Abstract][Full Text] [Related]
2. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Fisch MJ; Howard KL; Einhorn LH; Sledge GW Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955 [TBL] [Abstract][Full Text] [Related]
4. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137 [TBL] [Abstract][Full Text] [Related]
5. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359 [TBL] [Abstract][Full Text] [Related]
7. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875 [TBL] [Abstract][Full Text] [Related]
8. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943 [TBL] [Abstract][Full Text] [Related]
9. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients. Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105 [TBL] [Abstract][Full Text] [Related]
10. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564 [TBL] [Abstract][Full Text] [Related]
13. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Reed E; Gupta-Burt S; Litterst CL; Poirier MC Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937 [TBL] [Abstract][Full Text] [Related]
15. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732 [TBL] [Abstract][Full Text] [Related]
16. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors. Culine S; Philippot I; Farhat F; Théodore C; Terrier-Lacombe MJ; Droz JP Bull Cancer; 1997 Apr; 84(4):368-72. PubMed ID: 9238159 [TBL] [Abstract][Full Text] [Related]
18. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996]. Fléchon A; Biron P; Philip I; Blay JY; Droz JP Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344 [TBL] [Abstract][Full Text] [Related]
19. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477 [TBL] [Abstract][Full Text] [Related]
20. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy. Pectasides D; Pectasides M; Farmakis D; Nikolaou M; Koumpou M; Kostopoulou V; Mylonakis N Eur Urol; 2004 Feb; 45(2):187-93. PubMed ID: 14734005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]